Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ranbaxy Mum On Lipitor Plans, Advises Patience Until Nov. 30 When "Reality" Will Emerge

This article was originally published in PharmAsia News

You may also be interested in...



Ranbaxy's Anti-Malarial Approval Makes It First Indian Firm To Fully Develop An NCE

MUMBAI - For Ranbaxy Laboratories Ltd., it has been nearly a decade-long bumpy ride to discover and develop its anti-malarial compound, but India's regulator - the Drug Controller General of India - finally granted the company a conditional approval to market the compound

Ranbaxy Woes Continue With 30-plus Product Import Alert

FDA will lift a portion of its import alert for generic drugs made in two of Ranbaxy's facilities to allow the company to import antiviral ganciclovir to avoid a drug shortage

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC076890

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel